Daxor Announces Significant Blood Volume Data Using the BVA-100 Reported at Heart Failure Society of America Annual Scientific Meeting.

NEW YORK -- Daxor Corporation (AMEX:DXR), a medical instrumentation and biotechnology company, today announced significant results from blood volume data utilizing Daxor's BVA-100 was reported at the Heart Failure Society of America's (HFSA) Annual Scientific Meeting held last week in Seattle, WA. The studies were reported by physicians from Columbia Presbyterian's College of Physicians and Surgeons.

The studies involved identifying and treating anemia in diastolic heart failure, a subset of heart failure. In one study, 92% of diastolic heart failure patients had true anemia. An increase in plasma volume often occurs in heart failure, which may cause a false or "pseudo anemia". By utilizing Daxor's Blood Volume Analyzer BVA-100, which provides a precise measured plasma and red blood cell volume, clinicians were able to accurately diagnose and treat patients with a true anemia with epoetin alfa (EPO). EPO, the drug commonly used to treat anemia by stimulating the body to produce more red blood cells, is manufactured by Amgen, Inc.

Significant improvement in a patient's exercise capacity and heart function was observed in patients in this study. The use of erythropoietic therapies may increase the risk of thrombotic events (clots) and other serious events especially if a patient's blood volume is not correctly diagnosed. Treating true anemic diastolic heart failure patients with EPO demonstrated an increase in red blood cell volume without any adverse effects. Daxor's Blood Volume Analyzer BVA-100 provided an accurate diagnosis of patients' blood volume, affording a more precise treatment to avoid under or over treatment with EPO. A BVA may help achieve the potential full benefits of EPO use in patients with true anemia.

Previous studies have demonstrated that physicians have difficulty diagnosing patient volume status by clinical exam and standard laboratory tests. Studies utilizing the BVA-100 have demonstrated that a correct blood volume diagnosis and treatment to a normal blood volume resulted in improved outcomes. One of the therapy goals in heart failure is to achieve a normal blood volume status.

Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website www.Daxor.com.